Literature DB >> 27742500

Sclerostin deficiency in humans.

Antoon H van Lierop1, Natasha M Appelman-Dijkstra1, Socrates E Papapoulos2.   

Abstract

Sclerosteosis and van Buchem disease are two rare bone sclerosing dysplasias caused by genetic defects in the synthesis of sclerostin. In this article we review the demographic, clinical, biochemical, radiological, and histological characteristics of patients with sclerosteosis and van Buchem disease that led to a better understanding of the role of sclerostin in bone metabolism in humans and we discuss the relevance of these findings for the development of new therapeutics for the treatment of patients with osteoporosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone formation; Bone resorption; Sclerosteosis; Sclerostin; Van Buchem disease

Mesh:

Substances:

Year:  2016        PMID: 27742500     DOI: 10.1016/j.bone.2016.10.010

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  26 in total

1.  Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania.

Authors:  Amanda L Scheiber; David K Barton; Basma M Khoury; Joan C Marini; Donald L Swiderski; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2019-11-07       Impact factor: 6.741

Review 2.  Human Genetics of Sclerosing Bone Disorders.

Authors:  Raphaël De Ridder; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

3.  Sost deficiency leads to reduced mechanical strains at the tibia midshaft in strain-matched in vivo loading experiments in mice.

Authors:  Laia Albiol; Myriam Cilla; David Pflanz; Ina Kramer; Michaela Kneissel; Georg N Duda; Bettina M Willie; Sara Checa
Journal:  J R Soc Interface       Date:  2018-04       Impact factor: 4.118

4.  Environmental Toxins Are a Major Cause of Bone Loss.

Authors:  Joseph Pizzorno; Lara Pizzorno
Journal:  Integr Med (Encinitas)       Date:  2021-02

Review 5.  Novel insights into the coupling of osteoclasts and resorption to bone formation.

Authors:  Margaret M Durdan; Ruth D Azaria; Megan M Weivoda
Journal:  Semin Cell Dev Biol       Date:  2021-10-30       Impact factor: 7.727

Review 6.  WNT-β-catenin signalling - a versatile player in kidney injury and repair.

Authors:  Stefan J Schunk; Jürgen Floege; Danilo Fliser; Thimoteus Speer
Journal:  Nat Rev Nephrol       Date:  2020-09-28       Impact factor: 28.314

Review 7.  Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

Authors:  Michael R McClung
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-08-29       Impact factor: 5.346

Review 8.  Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk.

Authors:  Cy Fixen; Jennifer Tunoa
Journal:  Curr Osteoporos Rep       Date:  2021-01-07       Impact factor: 5.096

9.  Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis.

Authors:  Timothy Dreyer; Mittal Shah; Carl Doyle; Kevin Greenslade; Mark Penney; Paul Creeke; Apoorva Kotian; Hua Zhu Ke; Vinny Naidoo; Gill Holdsworth
Journal:  J Orthop Translat       Date:  2021-06-21       Impact factor: 5.191

10.  Ablation of Fat Cells in Adult Mice Induces Massive Bone Gain.

Authors:  Wei Zou; Nidhi Rohatgi; Jonathan R Brestoff; Yongjia Li; Ruteja A Barve; Eric Tycksen; Yung Kim; Matthew J Silva; Steven L Teitelbaum
Journal:  Cell Metab       Date:  2020-10-06       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.